

Sandra M Swain

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3027471/sandra-m-swain-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

278 papers	31,523 citations	70 h-index	176 g-index
301 ext. papers	36,503 ext. citations	7.8 avg, IF	6.95 L-index

#	Paper	IF	Citations
278	Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).. <i>Breast Cancer Research and Treatment</i> , 2022 , 193, 555	4.4	1
277	Abstract P1-07-04: Potential role of the antibody-dependent cellular phagocytosis (ADCP) in tumors achieving pCR in NRG Oncology/NSABP B-52. <i>Cancer Research</i> , 2022 , 82, P1-07-04-P1-07-04	10.1	
276	Abstract PD15-05: Assessment of estrogen receptor (ESR1) mRNA expression for prediction of extended aromatase inhibitor benefit in HR-positive breast cancer using NRG Oncology/NSABP B-42. <i>Cancer Research</i> , 2022 , 82, PD15-05-PD15-05	10.1	
275	Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.. <i>Cancer Treatment Reviews</i> , 2022 , 106, 102378	14.4	4
274	Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer.. <i>ESMO Open</i> , 2022 , 7, 100475	6	0
273	Best-worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy.. <i>Implementation Science Communications</i> , 2022 , 3, 52	2.2	0
272	BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. <i>Cancers</i> , 2022 , 14, 2596	6.6	1
271	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100896	2.2	3
270	The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profiling. <i>Journal of Translational Medicine</i> , 2021 , 19, 480	8.5	1
269	Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
268	Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1091-1091	2.2	0
267	HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. <i>Npj Breast Cancer</i> , 2021 , 7, 56	7.8	24
266	Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 502-502	2.2	5
265	Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. <i>Breast Cancer Research and Treatment</i> , 2021 , 185, 863-868	4.4	3
264	Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. <i>Breast Cancer Research and Treatment</i> , 2021 , 188, 179-190	4.4	2
263	Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. <i>Cancers</i> , 2021 , 13,	6.6	7
262	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology</i> , <i>The</i> , 2021 , 22, 1139-1150	21.7	24

261	Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx Digital Spatial Profiler. <i>Cancers</i> , 2021 , 13,	6.6	6
260	Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy. <i>Clinical and Translational Science</i> , 2021 ,	4.9	2
259	NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response. <i>Clinical Cancer Research</i> , 2020 , 26, 4233-4241	12.9	6
258	Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. <i>Clinical Cancer Research</i> , 2020 , 26, 1105-1113	12.9	10
257	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2020 , 21, 519-530	21.7	159
256	Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 500-500	2.2	14
255	Assessment of primary care practitioners' attitudes and interest in pharmacogenomic testing. <i>Pharmacogenomics</i> , 2020 , 21, 1085-1094	2.6	11
254	NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. <i>Journal of Clinical Oncology</i> , 2020 , 38, 444-453	2.2	76
253	Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa058	4.6	1
252	Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings. <i>Clinical and Translational Science</i> , 2020 , 13, 618-627	4.9	13
251	Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. <i>Breast Cancer Research and Treatment</i> , 2020 , 184, 265-275	4.4	8
250	Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 1475	5.3	3
249	Risk factors for inflammatory and non-inflammatory breast cancer in North Africa. <i>Breast Cancer Research and Treatment</i> , 2020 , 184, 543-558	4.4	2
248	De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. <i>Oncologist</i> , 2020 , 25, e214-e222	5.7	15
247	Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination. <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 389-399	4.4	15
246	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2019 , 15, 1951-1961	3.6	33
245	Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 407-417	4.4	7
244	Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 867-871	9.7	24

243	Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. <i>Breast Cancer Research and Treatment</i> , 2019 , 175, 595-603	4.4	73
242	Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?. <i>Annals of Oncology</i> , 2019 , 30, 1044-1050	10.3	16
241	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019 , 393, 1440-1452	4.0	137
240	End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1020-1020	2.2	15
239	Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3132-3132	2.2	
238	Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. <i>Clinical Cancer Research</i> , 2019 , 25, 2433-2441	12.9	33
237	Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 88-99	21.7	58
236	Luminal A Breast Cancer and Molecular Assays: A Review. <i>Oncologist</i> , 2018 , 23, 556-565	5.7	56
235	Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. <i>Annals of Oncology</i> , 2018 , 29, 646-653	10.3	74
234	Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. <i>Journal of the National Cancer Institute</i> , 2018 , 110,	9.7	54
233	Take care of your neighborhood. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 225-234	4.4	3
232	SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1038-1038	2.2	7
231	IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS1115-TPS1115	2.2	1
230	CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities. <i>Pharmacology & Therapeutics</i> , 2018 , 191, 65-73	13.9	41
229	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology, The</i> , 2018 , 19, 27-39	31.7	413
228	Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. <i>Annals of Oncology</i> , 2017 , 28, 761-768	10.3	24
227	SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. <i>Oncologist</i> , 2017 , 22, 518-525	5.7	25
226	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. <i>Lancet Oncology, The</i> , 2017 , 18, 52-62	21.7	164

225	3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). <i>Breast</i> , 2017 , 31, 244-259	3.6	137
224	Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1641-1649 ^{2.2}		348
223	Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). <i>Journal of Clinical Oncology</i> , 2017 , 35, 2647-2655	2.2	144
222	Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2656-2665	2.2	39
221	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1688-1700	21.7	328
220	Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. <i>JAMA Oncology</i> , 2017 , 3, 335-341	13.4	56
219	The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. <i>Annals of Surgical Oncology</i> , 2017 , 24, 1853-1860	3.1	7
218	HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens. <i>Clinical Breast Cancer</i> , 2017 , 17, 76-78	3	11
217	Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. <i>Clinical Breast Cancer</i> , 2017 , 17, 48-54.e3	3	7
216	Video intervention increases participation of black breast cancer patients in therapeutic trials. <i>Npj Breast Cancer</i> , 2017 , 3, 36	7.8	7
215	Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial. <i>Annals of Oncology</i> , 2017 , 28, 2761-2767	10.3	7
214	Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (MBC) previously treated with pertuzumab (P).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1023-1023	2.2	4
213	Experience and impact of alopecia in patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 239-239	2.2	
212	Genomic profiling of breast cancer in African-American women using MammaPrint. <i>Breast Cancer Research and Treatment</i> , 2016 , 159, 481-8	4.4	7
211	Cardiac Protection in HER2-Targeted Treatment: How Should We Measure New Strategies?. <i>JAMA Oncology</i> , 2016 , 2, 1037-9	13.4	7
210	Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 285-93	4.4	17
209	The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 235-51	4.4	14
208	Pertuzumab for the treatment of breast cancer: a safety review. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 853-63	4.1	14

207	Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 51-9	4	25
206	A phase I study of the CDK4/6 inhibitor, palbociclib plus 5-fluorouracil (5FU) in patients with advanced solid tumor malignancies (NCT01522989).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2589-2589	2.2	2
205	Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 501-501	2.2	16
204	Oncotype DX Recurrence Score and treatment choices according to ethnicity.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e12010-e12010	2.2	
203	Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned?. <i>Oncologist</i> , 2016 , 21, 399-401	5.7	1
202	Focus on You: Cancer clinical trials perspectives. <i>Contemporary Clinical Trials Communications</i> , 2016 , 4, 170-178	1.8	3
201	Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study. <i>Breast Cancer Research and Treatment</i> , 2015 , 149, 163-9	4.4	14
200	Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. <i>Lancet, The</i> , 2015 , 386, 1353-1361	4.0	447
199	Treatment of HER2-positive metastatic breast cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 1964-5	59.2	11
198	Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. <i>Lancet Oncology, The</i> , 2015 , 16, 1037-1048	21.7	115
197	Reply to a. Avan et Al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1712	2.2	1
196	Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age. <i>Advances in Therapy</i> , 2015 , 32, 1222-36	4.1	24
195	Does CDKN2A loss predict palbociclib benefit?. <i>Current Oncology</i> , 2015 , 22, e498-501	2.8	15
194	Improving Documentation of Pain Management at MedStar Washington Cancer Institute. <i>Journal of Oncology Practice</i> , 2015 , 11, 155-7	3.1	12
193	IN03 IS THERE AN OPTIMAL TREATMENT SEQUENCE FOR HER2 POSITIVE ADVANCED BREAST CANCER?. <i>Breast</i> , 2015 , 24, S21-S22	3.6	
192	Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1340-7	2.2	88
191	Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 724-34	59.2	1242
190	Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with HER2-positive metastatic breast cancer (MBC) in the phase III trial CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 598-598	2.2	3

189	Trends in the use of adjuvant therapy for women with breast cancer under age 65.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17541-e17541	2.2	1
188	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet, The</i> , 2014 , 384, 164-72	4.0	2177
187	Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. <i>Lancet, The</i> , 2014 , 383, 2127-35	4.0	1237
186	Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. <i>Oncologist</i> , 2014 , 19, 693-701	5.7	48
185	Reply to E.J. Moylan et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 606-7	2.2	
184	Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence. <i>Progress in Pediatric Cardiology</i> , 2014 , 36, 39-49	0.4	26
183	Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. <i>Annals of Oncology</i> , 2014 , 25, 1116-21	10.3	133
182	The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. <i>BMC Cancer</i> , 2014 , 14, 307	4.8	20
181	Pertuzumab for the treatment of breast cancer. <i>Cancer Investigation</i> , 2014 , 32, 430-8	2.1	12
180	Erratum to NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors [Evidence-based Complementary and Alternative Medicine, 2014 , 2014, 1-2	2.3	78
179	Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. <i>Cancer</i> , 2014 , 120, 2657-64	6.4	34
178	Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3753-61	2.2	243
177	Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3744-52	2.2	572
176	Locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC): Pooled-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 61-61	2.2	15
175	Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014). <i>Ecancermedicalscience</i> , 2014 , 8, 433	2.7	11
174	Genomic profiling of breast cancer in African American women.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11067-11067	2.2	
173	Increasing participation in breast cancer research: (INSPIRE-BrC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 53-53	2.2	0
172	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2013 , 14, 1183-92	21.7	268

171	Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3197-204	2.2	107
170	Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1782-8	9.7	72
169	Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). <i>Breast Cancer Research and Treatment</i> , 2013 , 142, 89-99	4.4	46
168	Phase I trial of dasatinib and ixabepilone in patients with solid tumors. <i>Investigational New Drugs</i> , 2013 , 31, 92-8	4.3	7
167	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , 2013 , 14, 461-71	21.7	687
166	Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 779-90	5.4	10
165	NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013 , 2013, 964592	2.3	20
164	Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. <i>Annals of Oncology</i> , 2013 , 24, 2630-2635	10.3	54
163	Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. <i>Anti-Cancer Drugs</i> , 2013 , 24, 1084-92	2.4	17
162	Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. <i>Clinical Cancer Research</i> , 2013 , 19, 3681-92	12.9	48
161	Insights from the cancer center business summit: preparing for the future. Foreword. <i>Journal of Oncology Practice</i> , 2013 , 9, 69	3.1	1
160	A Passion for Solving the Puzzle of Cancer: Jane Cooke Wright, M.D., 1919-2013. <i>Oncologist</i> , 2013 , 18, 646-648	5.7	1
159	Adjuvant trastuzumab: does time really matter?. <i>Oncologist</i> , 2013 , 18, 490-2	5.7	3
158	What currently defines a breast center? Initial data from the national accreditation program for breast centers. <i>Journal of Oncology Practice</i> , 2013 , 9, e62-70	3.1	10
157	ASCO's approach to a learning health care system in oncology. <i>Journal of Oncology Practice</i> , 2013 , 9, 145-8	3.1	39
156	Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia. <i>Cancer Medicine</i> , 2013 , 2, 178-84	4.8	16
155	Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. <i>Oncologist</i> , 2013 , 18, 257-64	5.7	107
154	ExposureEfficacy relationship of trastuzumab emtansine (T-DM1) in EMILIA, a phase III study of T-DM1 versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 644-644	2.2	3

153	Exposure-safety relationship of trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 646-646	2.2	9
152	NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS1139-TPS1139	2.2	3
151	Genomic profiling of breast cancer in African-American women.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11054-11054	2.2	
150	Cultural competency training for health care providers in an urban cancer institute and impact on breast care.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6561-6561	2.2	
149	Lessons learned from the development of the CancerLinQ prototype: Clinical decision support.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 237-237	2.2	
148	Twenty-five year results of the national cancer institute randomized breast conservation trial. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 197-203	4.4	56
147	Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. <i>Lancet, The</i> , 2012 , 379, 432-44	4.0	1372
146	Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. <i>Lancet Oncology, The</i> , 2012 , 13, 734-42	21.7	144
145	Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer. <i>Clinical Breast Cancer</i> , 2012 , 12, 232-9	3	14
144	Pazopanib for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 217-25	5.9	10
143	Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 109-19	59.2	1752
142	Bevacizumab added to neoadjuvant chemotherapy for breast cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 310-20	59.2	361
141	Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3792-9	2.2	361
140	A Pilot Study of a Culturally Targeted Video Intervention to Increase Participation of African American Patients in Cancer Clinical Trials. <i>Oncologist</i> , 2012 , 17, 708-714	5.7	18
139	Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1268-73	2.2	249
138	Patient navigation significantly reduces delays in breast cancer diagnosis in the District of Columbia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1655-63	4	55
137	A pilot study of a culturally targeted video intervention to increase participation of African American patients in cancer clinical trials. <i>Oncologist</i> , 2012 , 17, 708-14	5.7	21
136	NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1025-1025	2.2	1

135	Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 533-533	2.2	4
134	Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 597-597	2.2	7
133	Quality of life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 598-598	2.2	6
132	Concordance between independently and investigator-assessed progression-free survival in CLEOPATRA.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e11055-e11055	2.2	1
131	A critical review of the enrollment of black patients in cancer clinical trials. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 153-7	7.1	12
130	The Role of the Multidisciplinary Team in Inflammatory Breast Cancer 2012 , 121-126		1
129	NSABP B-47: A phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of docetaxel plus cyclophosphamide or four cycles of doxorubicin plus cyclophosphamide followed by weekly paclitaxel) to chemotherapy plus trastuzumab in women with node-positive or high-risk, node-negative, HER2-low invasive breast cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS1142-TPS1142	2.2	
128	Clinical trials decision-making in African American patients with cancer: The role of cancer-coping religious beliefs.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e16543-e16543	2.2	
127	p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer. <i>International Journal of Oncology</i> , 2011 , 38, 1445-52	4.4	10
126	Ixabepilone: clinical role in metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2011 , 11, 139-45	3	17
125	Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. <i>Clinical Breast Cancer</i> , 2011 , 11, 228-34	3	16
124	International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. <i>Annals of Oncology</i> , 2011 , 22, 515-523	10.3	321
123	Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 478-88	9.7	515
122	Chemotherapy: updates and new perspectives. <i>Oncologist</i> , 2011 , 16 Suppl 1, 30-9	5.7	16
121	Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1110-6	2.2	89
120	Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side?. <i>Journal of Clinical Oncology</i> , 2011 , 29, 603-6	2.2	26
119	Cardiac dysfunction after cancer treatment. <i>Texas Heart Institute Journal</i> , 2011 , 38, 248-52	0.8	11
118	Amenorrhea from breast cancer therapy--not a matter of dose. <i>New England Journal of Medicine</i> , 2010 , 363, 2268-70	59.2	52

117	Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. <i>New England Journal of Medicine</i> , 2010 , 362, 2053-65	59.2	237
116	Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2974-81	2.2	46
115	Chemotherapy: updates and new perspectives. <i>Oncologist</i> , 2010 , 15 Suppl 5, 8-17	5.7	16
114	The impact of systemic therapy following ductal carcinoma in situ. <i>Journal of the National Cancer Institute Monographs</i> , 2010 , 2010, 200-3	4.8	14
113	CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2010 , 10, 489-91	3	106
112	Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 119, 685-99	4.4	70
111	Primary systemic chemotherapy for inflammatory breast cancer. <i>Cancer</i> , 2010 , 116, 2821-8	6.4	19
110	Reply to the Letter to the Editor from Jubb. <i>Clinical Cancer Research</i> , 2009 , 15, 414.2-414	12.9	1
109	The influence of a gene expression profile on breast cancer decisions. <i>Journal of Surgical Oncology</i> , 2009 , 99, 319-23	2.8	72
108	Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. <i>Breast Cancer Research and Treatment</i> , 2009 , 113, 315-20	4.4	82
107	Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. <i>Nature Reviews Cancer</i> , 2009 , 9, 463-75	11.3	881
106	Ixabepilone for the treatment of solid tumors: a review of clinical data. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 423-35	5.9	15
105	Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. <i>Journal of Proteome Research</i> , 2008 , 7, 1508-17	5.6	113
104	Locally advanced and inflammatory breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 786-90	2.2	136
103	Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 5893-9	12.9	75
102	Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. <i>Clinical Cancer Research</i> , 2008 , 14, 14-24	12.9	246
101	First, do no harm. <i>Onkologie</i> , 2008 , 31, 511-2		4
100	Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 2710-6	12.9	137

99	The epothilones: translating from the laboratory to the clinic. <i>Clinical Cancer Research</i> , 2008 , 14, 1618-24	12.9	55
98	Circulating biomarkers of bevacizumab activity in patients with breast cancer. <i>Cancer Biology and Therapy</i> , 2008 , 7, 15-20	4.6	30
97	Therapeutic strategies for triple-negative breast cancer. <i>Cancer Journal (Sudbury, Mass.)</i> , 2008 , 14, 343-51	12.2	58
96	Cardiovascular complications of breast cancer therapy. <i>Clinical Advances in Hematology and Oncology</i> , 2008 , 6, 247-8, 282	0.6	1
95	Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. <i>Clinical Advances in Hematology and Oncology</i> , 2008 , 6, 455-67	0.6	89
94	A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. <i>Investigational New Drugs</i> , 2007 , 25, 545-51	4.3	19
93	A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. <i>Breast Cancer Research and Treatment</i> , 2007 , 103, 177-83	4.4	35
92	Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience. <i>Radiology</i> , 2007 , 244, 727-35	20.5	65
91	Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3421-7	2.2	146
90	Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. <i>Oncology Reports</i> , 2007 ,	3.5	5
89	Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. <i>Investigational New Drugs</i> , 2007 , 25, 63-7	4.3	39
88	Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. <i>Oncology Reports</i> , 2007 , 17, 281-7	3.5	43
87	A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2006 , 6, 535-9	3	39
86	A step in the right direction. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3717-8	2.2	13
85	Emerging drugs to replace current leaders in first-line therapy for breast cancer. <i>Expert Opinion on Emerging Drugs</i> , 2006 , 11, 489-501	3.7	11
84	A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer. <i>Oncology</i> , 2006 , 71, 306-8	3.6	16
83	Influence of garlic (<i>Allium sativum</i>) on the pharmacokinetics of docetaxel. <i>Clinical Cancer Research</i> , 2006 , 12, 4636-40	12.9	66
82	Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2084-91	2.2	38

81	Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 769-77	2.2	459
80	Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5769-79	2.2	271
79	Peripheral neuropathy induced by microtubule-stabilizing agents. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1633-42	2.2	371
78	Inflammatory Breast Cancer. <i>Breast Disease</i> , 2006 , 22, 1-1	1.6	2
77	Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 6226-32	12.9	32
76	Concepts and clinical trials of dose-dense chemotherapy for breast cancer. <i>Clinical Breast Cancer</i> , 2005 , 6, 402-11	3	7
75	Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. <i>New England Journal of Medicine</i> , 2005 , 353, 1673-84	59.2	4284
74	Clinical aspects of inflammatory breast cancer. <i>Breast Disease</i> , 2005 , 22, 35-44	1.6	63
73	Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). <i>Seminars in Oncology</i> , 2005 , 32, S22-6	5.5	55
72	A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer. <i>Clinical Breast Cancer</i> , 2005 , 6, 460-3	3	5
71	Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2726-34	2.2	201
70	Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. <i>Annals of Oncology</i> , 2005 , 16, 1297-304	10.3	31
69	Contralateral breast cancer: where does it all begin?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4585-7	2.2	6
68	Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7811-9	2.2	626
67	Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C) -k docetaxel (T) arm of NSABP B-30: Preliminary results. <i>Journal of Clinical Oncology</i> , 2005 , 23, 537-537	2.2	8
66	Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 5038-47	12.9	62
65	Ductal carcinoma in situ, complexities and challenges. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 906-20	9.7	291
64	A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 6764-9	12.9	33

63	Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 516-23	9.7	81
62	RESPONSE: Re: Estrogen Receptor Status of Primary Breast Cancer Is Predictive of Estrogen Receptor Status of Contralateral Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 1041-1041	9.7	1
61	Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4067-74	2.2	149
60	Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3080-90	2.2	157
59	CA 125 elevation in breast cancer: a case report and review of the literature. <i>Breast Journal</i> , 2004 , 10, 146-9	1.2	16
58	The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004 , 130, 1-7	4.9	124
57	Indications for Neoadjuvant Therapy in Breast Cancer. <i>Seminars in Breast Disease</i> , 2004 , 7, 58-60		
56	A phase 2 trial of BMS-247550 (ixabepilone), an epothilone B analog, given daily x 5 in breast cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 545-545	2.2	2
55	A pilot study to evaluate response and angiogenesis after treatment with bevacizumab in patients with inflammatory breast cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 578-578	2.2	4
54	Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. <i>Cancer</i> , 2003 , 97, 2869-79	6.4	1432
53	Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003 , 796, 181-8	3.2	43
52	Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. <i>Journal of Clinical Investigation</i> , 2003 , 111, 81-90	15.9	406
51	Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. <i>Journal of Clinical Investigation</i> , 2003 , 111, 81-90	15.9	222
50	Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4074-82	2.2	116
49	Oophorectomy in carriers of BRCA mutations. <i>New England Journal of Medicine</i> , 2002 , 347, 1037-40; author reply 1037-40	59.2	7
48	Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy. <i>Seminars in Oncology</i> , 2002 , 29, 77-85	5.5	39
47	Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. <i>Clinical Cancer Research</i> , 2002 , 8, 3857-62	12.9	55
46	RESPONSE: Re: Tamoxifen and Contralateral Breast Cancer: the Other Side. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 1753-1754	9.7	

45	Tamoxifen and contralateral breast cancer: the other side. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 963-5	9.7	12
44	Novel agents: Clinical trial design. <i>Seminars in Oncology</i> , 2001 , 28, 148-153	5.5	3
43	Adjuvant chemotherapy for breast cancer: An update. <i>Seminars in Oncology</i> , 2001 , 28, 359-376	5.5	15
42	Tumor markers: should we or shouldn't we?. <i>Cancer Journal (Sudbury, Mass)</i> , 2001 , 7, 175-7	2.2	6
41	Tamoxifen for patients with estrogen receptor-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 93S-97S	2.2	15
40	Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. <i>Clinical Transplantation</i> , 2000 , 14, 32-41	3.8	15
39	Doxorubicin-induced cardiomyopathy. <i>New England Journal of Medicine</i> , 1999 , 340, 653-4; author reply 655	59.2	22
38	Locally advanced noninflammatory breast cancer. <i>Cancer Investigation</i> , 1999 , 17, 211-9	2.1	6
37	Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. <i>Journal of Clinical Oncology</i> , 1997 , 15, 1318-32	2.2	460
36	Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. <i>Journal of Clinical Oncology</i> , 1997 , 15, 1333-40	2.2	202
35	Tamoxifen: the long and short of it. <i>Journal of the National Cancer Institute</i> , 1996 , 88, 1510-2	9.7	18
34	Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life. <i>Journal of Clinical Oncology</i> , 1996 , 14, 1565-72	2.2	30
33	Phase I trial of pentosan polysulfate. <i>Investigational New Drugs</i> , 1995 , 13, 55-62	4.3	16
32	A phase II trial of paclitaxel (Taxol) as first line treatment in advanced breast cancer. <i>Investigational New Drugs</i> , 1995 , 13, 217-22	4.3	18
31	Phase II study of oral etoposide for patients with advanced breast cancer. <i>Cancer</i> , 1995 , 76, 2485-90	6.4	20
30	Clinical breast cancer research core. <i>Breast Cancer Research and Treatment</i> , 1994 , 31, 371-5	4.4	
29	Mitoxantrone, 5-FU, and leucovorin in breast cancer. <i>Medical and Pediatric Oncology</i> , 1994 , 22, 370-4		2
28	Results of concomitantly administered chemoradiation for locally advanced noninflammatory breast cancer. <i>Seminars in Radiation Oncology</i> , 1994 , 4, 226-235	5.5	10

27	Can we increase survival in breast cancer with innovative applications of conventional drugs?. <i>European Journal of Cancer</i> , 1994 , 30A, 423-4	7.5	
26	Hormone replacement therapy in women with a history of breast carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 1994 , 8, 179-95	3.1	1
25	Heparin-binding growth factor blockade with pentosan polysulfate. <i>Annals of the New York Academy of Sciences</i> , 1993 , 698, 63-70	6.5	5
24	In situ or localized breast cancer--how much treatment is needed?. <i>New England Journal of Medicine</i> , 1993 , 328, 1633-4	59.2	8
23	Detectable inhibition of heparin-binding growth factor activity in sera from patients treated with pentosan polysulfate. <i>Journal of the National Cancer Institute</i> , 1993 , 85, 1068-73	9.7	27
22	Ductal carcinoma in situ. <i>Cancer Investigation</i> , 1992 , 10, 443-54	2.1	17
21	Therapy of patients with metastatic breast cancer with 5-fluorouracil, leucovorin and carboplatin. <i>Anti-Cancer Drugs</i> , 1992 , 3, 463-9	2.4	4
20	Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. <i>Journal of Clinical Oncology</i> , 1992 , 10, 976-83	2.2	276
19	The effect of systemic therapy on local-regional control in locally advanced breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992 , 23, 949-60	4	69
18	Reimbursement for solid tumor autologous bone marrow transplantation trials: a strategy for ensuring continuation of a promising therapy. <i>Cancer Investigation</i> , 1991 , 9, 93-7	2.1	5
17	Adjuvant therapy in early breast cancer. <i>American Family Physician</i> , 1991 , 44, 453-62	1.3	3
16	Locally Advanced Breast Cancer: The National Cancer Institute Experience 1991 , 416-434		1
15	Selection of therapy for stage III breast cancer. <i>Surgical Clinics of North America</i> , 1990 , 70, 1061-80	4	20
14	The effects of hormonal and chemotherapy on tumoral and nonneoplastic breast tissue. <i>Human Pathology</i> , 1990 , 21, 192-8	3.7	62
13	Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer. <i>American Surgeon</i> , 1990 , 56, 6-11	0.8	32
12	Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 1989 , 7, 890-9	2.2	207
11	Treatment of stage III breast cancer. A panel discussion. <i>Breast Cancer Research and Treatment</i> , 1989 , 13, 225-35	4.4	6
10	Locally advanced breast cancer. <i>Current Opinion in Oncology</i> , 1989 , 1, 318-23	4.2	

9	Noninvasive breast cancer: Part 1. Ductal carcinoma in situ--incidence, presentation, guidelines to treatment. <i>Oncology</i> , 1989 , 3, 25-31; discussion 40, 42, 44 passim	1.8	1
8	Noninvasive breast cancer: Part 2. Lobular carcinoma in situ--incidence, presentation, guidelines to treatment. <i>Oncology</i> , 1989 , 3, 35-40; discussion 40, 42, 44 passim	1.8	
7	Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. <i>Cancer Research</i> , 1989 , 49, 4185-91	10.1	43
6	Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer--a randomized study. <i>Breast Cancer Research and Treatment</i> , 1988 , 12, 51-7	4.4	4
5	Salvage treatment with intermediate-dose methotrexate and 5-fluorouracil in metastatic breast cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1988 , 11, 445-7	2.7	
4	Controversies in the treatment of cancer of the breast. <i>Annual Review of Medicine</i> , 1987 , 38, 287-94	17.4	2
3	Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. <i>Cancer Research</i> , 1987 , 47, 3889-94	10.1	186
2	8th San Antonio Breast Cancer Symposium--Plenary lecture. Autocrine and paracrine growth regulation of human breast cancer. <i>Breast Cancer Research and Treatment</i> , 1986 , 7, 59-70	4.4	227
1	Autocrine and paracrine growth regulation of human breast cancer. <i>The Journal of Steroid Biochemistry</i> , 1986 , 24, 147-54		104